Capricor's DMD therapy lacks efficacy, FDA says ahead of adcomm
The FDA is again questioning the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday. The agency's review team said it was unable to identify ...
July 27, 2026 01:40 PM EDTUpdated 02:21 PM FDA+ Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm Zachary Brennan Senior Editor The FDA is again questioning the efficacy of Capricor’s cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that